Saturday 17 October 2026
Export IART’s income statement to Excel — free account
Integra LifeSciences Holdings Corporation
IART Healthcare Medical Devices
Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 101.0%, free cash flow grew 193.5% and total debt rose 1.51%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
13.21
0.32
−2.37%
Follow IART
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.67 | 0.58 | 0.44 | 0.84 | |
P/FCF ratio |
0.00 | 0.00 | 177.67 | 53.80 | |
P/Operating CF |
26.89 | 80.59 | 73.94 | 60.88 | |
P/B ratio |
1.06 | 0.91 | 0.70 | 1.33 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.95 | 1.53 | 1.44 | 1.84 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 13.56 | |
EV/Operating CF |
35.82 | 49.74 | 33.23 | 35.52 | |
EV/FCF |
(708.68) | (80.70) | 581.82 | 117.46 | |
Quick Ratio |
1.46 | 1.19 | 1.53 | 1.64 | |
Current Ratio |
3.14 | 2.54 | 3.38 | 3.60 | |
Net Debt/EBITDA |
29.55 | 24.86 | 30.67 | 26.60 | |
Debt/Assets |
49.15% | 50.45% | 51.06% | 51.32% | |
Debt/Equity |
1.73 | 1.74 | 1.75 | 1.75 | |
Asset Turnover |
0.43 | 0.43 | 0.43 | 0.46 | |
Operating CF/Net income |
(7.57) | (6.93) | (2.12) | 5.09 | |
Capex/Depreciation |
(0.38) | (0.44) | (0.38) | (0.31) | |
Interest Coverage |
0.52 | 0.97 | 0.51 | 0.84 | |
Research and Development Expense of Revenue |
5.59% | 5.70% | 6.00% | 5.79% | |
Selling, General and Administrative Expense of Revenue |
42.04% | 38.92% | 45.48% | 41.18% | |
Intangible Assets out of Total Assets |
0.49 | 0.49 | 0.48 | 0.47 | |
Share Based Compensation of Revenue |
1.39% | 1.34% | 1.32% | 1.40% | |
Graham Net Nets |
(1.33) | (1.47) | (1.88) | (0.96) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(45.08%) | (54.19%) | (68.58%) | (0.50%) | |
Free Cash Flow Yield |
(0.41%) | (3.26%) | 0.56% | 1.86% | |
Revenue per Share |
5.24 | 5.67 | 5.09 | 5.42 | |
Operating CF per Share |
0.53 | 0.15 | 0.13 | 0.30 | |
Capex per Share |
(0.20) | (0.22) | (0.19) | (0.16) | |
Free Cash Flow per Share |
0.34 | (0.07) | (0.07) | 0.14 | |
Cash per Share |
3.49 | 3.44 | 3.45 | 3.55 | |
Shareholders Equity per Share |
13.52 | 13.61 | 13.55 | 13.50 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.52 | 13.61 | 13.55 | 13.50 | |
Free Cash Flow |
25.75 | (5.40) | (5.04) | 10.50 | |
Working Capital |
779.53 | 703.56 | 825.17 | 860.60 | |
Capital Expenditures |
(15.16) | (17.21) | (14.85) | (12.31) | |
Net Current Asset Value |
(1,465.30) | (1,398.99) | (1,363.30) | (1,328.63) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 46.23 | |
Capex to Sales |
0.04 | 0.04 | 0.04 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 21.18 | |
| Other line items | |||||
Average Receivables |
255.23 | 275.61 | 258.43 | 275.85 | |
Average Payables |
84.99 | 89.11 | 89.62 | 87.74 | |
Average Inventory |
463.02 | 460.91 | 470.23 | 478.57 | |
Average Assets |
3,856.13 | 3,819.71 | 3,815.24 | 3,615.70 | |
Average Common Equity |
1,279.58 | 1,294.37 | 1,283.27 | 1,041.02 |
Columns are period end dates